{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:52:18Z","timestamp":1792788738666,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Millennium Pharmaceuticals, Inc.","id":[{"id":"https:\/\/ror.org\/05vm7p871","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.ygyno.2012.06.040","type":"journal-article","created":{"date-parts":[[2012,7,6]],"date-time":"2012-07-06T06:30:41Z","timestamp":1341556241000},"page":"63-69","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":120,"title":["Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma"],"prefix":"10.1016","volume":"127","clinical-trial-number":[{"clinical-trial-number":"nct01091428","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01482962","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Ursula A.","family":"Matulonis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudarshan","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharad","family":"Ghamande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore A.","family":"Del Prete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elzbieta","family":"Kutarska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Fingert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadi","family":"Danaee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell J.","family":"Schilder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2012.06.040_bb0005","series-title":"NCCN clinical practice guidelines in oncology (NCCN guidelines): ovarian cancer (including fallopian tube cancer and primary peritoneal cancer)","author":"National Comprehensive Cancer Network Inc.","year":"2011-2012"},{"key":"10.1016\/j.ygyno.2012.06.040_bb0010","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1028-4559(08)60007-8","article-title":"Management of relapsed\/refractory epithelial ovarian cancer: current standards and novel approaches","volume":"46","author":"Lin","year":"2007","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2012.06.040_bb0015","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.drup.2009.09.001","article-title":"Novel strategies for reversing platinum resistance","volume":"12","author":"Shahzad","year":"2009","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.ygyno.2012.06.040_bb0020","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ygyno.2004.08.028","article-title":"A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer","volume":"95","author":"Berkenblit","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2012.06.040_bb0025","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2012.06.040_bb0030","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ygyno.2005.10.036","article-title":"Phase II trial of weekly paclitaxel (80mg\/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study","volume":"101","author":"Markman","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2012.06.040_bb0035","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1200\/JCO.2006.09.6735","article-title":"Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer","volume":"25","author":"Mutch","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2012.06.040_bb0040","first-page":"721","article-title":"New advances in ovarian cancer","volume":"24","author":"Liu","year":"2010","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.ygyno.2012.06.040_bb0045","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1158\/1535-7163.MCT-09-0765","article-title":"Aurora kinase inhibitors\u2014rising stars in cancer therapeutics?","volume":"9","author":"Dar","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ygyno.2012.06.040_bb0050","first-page":"1420","article-title":"Activation and overexpression of centrosome kinase BTAK\/Aurora-A in human ovarian cancer","volume":"9","author":"Gritsko","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2012.06.040_bb0055","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s12672-011-0070-x","article-title":"Functional significance of Aurora kinase A regulatory interactions with p53\u2013ERalpha complex in human breast cancer cells","volume":"2","author":"Katayama","year":"2011","journal-title":"Horm Cancer"},{"key":"10.1016\/j.ygyno.2012.06.040_bb0060","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3727\/096504005775082101","article-title":"Frequent overexpression of STK15\/Aurora-A\/BTAK and chromosomal instability in tumorigenic cell cultures derived from human ovarian cancer","volume":"15","author":"Hu","year":"2005","journal-title":"Oncol Res"},{"key":"10.1016\/j.ygyno.2012.06.040_bb0065","doi-asserted-by":"crossref","first-page":"6153","DOI":"10.1158\/1078-0432.CCR-07-0671","article-title":"DNA replication licensing factors and aurora kinases are linked to aneuploidy and clinical outcome in epithelial ovarian carcinoma","volume":"13","author":"Kulkarni","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2012.06.040_bb0070","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1158\/1078-0432.CCR-07-0431","article-title":"Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients","volume":"13","author":"Landen","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2012.06.040_bb0075","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.1158\/1078-0432.CCR-06-2775","article-title":"Predictive value of Aurora-A\/STK15 expression for late stage epithelial ovarian cancer patients treated by adjuvant chemotherapy","volume":"13","author":"Lassmann","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2012.06.040_bb0080","doi-asserted-by":"crossref","first-page":"7614","DOI":"10.1158\/1078-0432.CCR-11-1536","article-title":"Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays","volume":"17","author":"Manfredi","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2012.06.040_bb0085","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-12-0571","article-title":"Phase 1 Pharmacokinetic\/Pharmacodynamic Study of MLN8237 \u2013 An Investigational, Oral, Selective Aurora A Kinase Inhibitor \u2013 In Patients With Advanced Solid Tumors","author":"Cervantes","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2012.06.040_bb0090","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-12-0589","article-title":"Phase 1 Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations","author":"Does","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2012.06.040_bb0095","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2012.06.040_bb0100","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1158\/1078-0432.CCR-03-0787","article-title":"Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer","volume":"10","author":"Rustin","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"Suppl. 8","key":"10.1016\/j.ygyno.2012.06.040_bb0105","doi-asserted-by":"crossref","first-page":"viii20","DOI":"10.1093\/annonc\/mdi963","article-title":"Clinical trials in ovarian carcinoma: study methodology","volume":"16","author":"Vermorken","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ygyno.2012.06.040_bb0110","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.cct.2010.07.008","article-title":"Two-stage designs optimal under the alternative hypothesis for phase II cancer clinical trials","volume":"31","author":"Mander","year":"2010","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.ygyno.2012.06.040_bb0115","series-title":"AACR annual meeting abstracts","article-title":"Pharmacodynamic\/pharmacokinetic\/efficacy relationships of MLN8237, a small-molecule inhibitor of Aurora A kinase","author":"Chakravarty","year":"2008"},{"key":"10.1016\/j.ygyno.2012.06.040_bb0120","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.1182\/blood-2009-12-259523","article-title":"A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma","volume":"115","author":"Gorgun","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ygyno.2012.06.040_bb0125","first-page":"iv135","article-title":"Multicenter phase II trial of MLN8237, an investigational inhibitor of aurora A kinase (AAK), in patients with aggressive B-cell and T-cell non-Hodgkin lymphoma","volume":"22","author":"Friedberg","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ygyno.2012.06.040_bb0130","first-page":"1341","article-title":"Phase 2 study of MLN8237, an investigational Aurora A kinase (AAK) inhibitor in patients with acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS)","volume":"116","author":"Goldberg","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ygyno.2012.06.040_bb0135","first-page":"1154","article-title":"Phase I study of an investigational Aurora A kinase inhibitor MLN8237 in patients with advanced hematologic malignancies","volume":"116","author":"Padmanabhan","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ygyno.2012.06.040_bb0140","first-page":"29","article-title":"Phase I dose-escalation study of the investigational Aurora A kinase (AAK) inhibitor MLN8237 as an enteric-coated tablet (ECT) formulation in patients with nonhematologic malignancies","author":"Sharma","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2012.06.040_bb0145","doi-asserted-by":"crossref","first-page":"6694","DOI":"10.1158\/1078-0432.CCR-09-1445","article-title":"A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors","volume":"15","author":"Cohen","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2012.06.040_bb0150","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/annonc\/mdq344","article-title":"Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors","volume":"22","author":"Boss","year":"2011","journal-title":"Ann Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581200491X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581200491X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:32:08Z","timestamp":1758771128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082581200491X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S009082581200491X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2012.06.040","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2012.06.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}